Bioteque (4107) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Bioteque stock TWD 148, price TWD 106, upside +39.6%, quality 79 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 84.35 TWD – 137.90 TWD · fair‑value band 102.54 TWD – 195.50 TWD · the 106.00 TWD price screens below the 148.01 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Bioteque in your weekly email
Every Wednesday you see whether Bioteque is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bioteque Corporation manufactures and sells medical devices in Asia, South America, North America, and internationally.
Show moreShow less
The company offers angiography catheter, balloon dilation catheter, guiding sheath, guide steel wire, y-type connector, multi-pipe joint, connecting pipe, y-type connector assembly, peripheral vascular guiding catheter, coronary balloon dilation catheter, central venous catheter, microcatheter assembly, injection tube sleeve assembly for radiographic catheters, micro-puncture guide assembly, closed suction catheter, oxygen masks and tubing, anesthesia mask, sprayer and spray mask, endotracheal tube, and tracheostomy tube.
It also provides pig tail drainage tube assembly, pig tail drainage tube, percutaneous drainage catheter accessories, insertion of drainage catheter kit, puncture and insertion system, snap lock drainage catheter set, ureteral catheter, propulsion tube, ureteral balloon dilation catheter, subcutaneous pyelostomy with ureteral catheterization, kidney transplantation ureteral catheter, tumor ureteral catheter, ureteroscopy applicable ureteral catheter, angle sleeve, and urinary tract stone removal products.
In addition, it offers blood circuit tube parts, deodorizing and antibacterial spray, biliary balloon dilation catheter, nasobiliary drainage catheter, surgical drainage catheter, leg-binding urine bag, and drainage bag, as well as PVC IV infusion bags, PVC pipe bags, accessories for infusion bags, infusion extension tubing, and IV set.
Bioteque Corporation was incorporated in 1991 and is headquartered in Taipei, Taiwan.
Stock analysis
Bioteque (4107) currently trades at 106.00 TWD, while our model-based Fair Value estimate is 148.01 TWD, implying the stock looks roughly 28% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 159.50 TWD per share, and 17 of the 26 models we run sit above the 106.00 TWD price.
Bear case: the Asset-Based group reads lowest at 18.47 TWD, and 9 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 102.54 TWD (bear) to 195.50 TWD (bull), the price of 106.00 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 79/100 (high quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Bioteque reported revenue of 2.1B TWD in FY2025 versus 1.8B TWD in FY2021, a compound +4.0%/yr. Reported net income was 539M TWD in FY2025, compounding +5.7%/yr from FY2021.
Key figures
Market cap 7.3B TWD (≈ $224M) Micro · P/E ratio 12.5 · P/S ratio 3.31 · EPS (TTM) 8.47 TWD · Dividend yield 5.2% · Net margin 26.5% · Return on equity 17.3% · Return on assets (EBIT) 13.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 79 out of 100 (medium confidence).
What moves the price
The share trades about 18% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 40%, 4107 screens cheaper than that median.
Fair Value models
Bear102.54 TWDFair Value 148.01 TWDBull195.50 TWD
Price 106.00 TWD · Upside +39.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2.56 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Start year 2020 (pandemic). Over 10 years: +5.4% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.1%
Dividend (yield on the price)5.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.1% vs 6.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.31% → 31%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −0.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 180 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score79 · Top 25%
Fair Value upside+39.6% · Top 25%
Profitability
Return on equity (12 months)17.3% · Top 25%
Return on assets11.6% · Top 25%
Net margin (12 months)26.5% · Top 25%
Operating margin (12 months)33.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)10.9% · Above median
Dividend yield (12 months)5.2% · Top 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bioteque Fair Value". https://www.fairvalue-calculator.com/stock/4107
Frequently asked questions
Is Bioteque (4107) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 148.01 TWD versus a price of 106.00 TWD, about +40% upside (undervalued).
What is the fair value of 4107?
Our model-based fair value for Bioteque is 148.01 TWD (as of Nov 6, 2026), built from audited fundamentals. The current price: 106.00 TWD.
What is the quality score of 4107?
Bioteque has a Quality Score of 79/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioteque (4107)?
Our model-based price target is the fair value of 148.01 TWD (as of Nov 6, 2026) from 26 valuation models. Cautious scenario 102.54 TWD, optimistic scenario 195.50 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Bioteque stock forecast for 2026?
Our models put fair value at 148.01 TWD, about +40% upside versus a price of 106.00 TWD (undervalued). Cautious scenario 102.54 TWD, optimistic scenario 195.50 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Bioteque (4107)?
Bioteque reported trailing-twelve-month revenue of about 2.2B TWD (latest available figure, as of Nov 6, 2026).
Does Bioteque pay a dividend?
Bioteque currently shows a dividend yield of 5.19% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Bioteque (4107) and when is the ex-dividend date?
Bioteque pays a dividend of 5.50 TWD per share a year, a dividend yield of 5.2%. The last ex-dividend date was Jul 28, 2026. A dividend has been paid every year since at least 2008. The payout ratio is 64.9% of earnings. Free cash flow covers the dividend 1.59 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Bioteque (4107)?
For today's price to be fair in a discounted-cash-flow model, Bioteque would have to grow free cash flow by +1.2 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.9 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 4107 use?
Our models discount Bioteque at 11.8 %: a base by market capitalisation (micro), damped by beta 0.14, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bioteque that is +1.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Bioteque (4107) delivered so far?
Over the past 5 years revenue at Bioteque grew +1.9 % a year. The price currently implies free-cash-flow growth of +1.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bioteque (4107) growing?
The median revenue growth in the sector is +6.3 % a year. That is the yardstick for the growth priced into Bioteque (+1.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bioteque (4107)?
The free-cash-flow yield on the price is 8.26 %: that much free cash flow Bioteque produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bioteque (4107)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bioteque it is 148.01 TWD per share (as of Nov 6, 2026), against a price of 106.00 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Bioteque stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 4107 trades below its calculated fair value: price 106.00 TWD, fair value 148.01 TWD, a gap of about +40% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4107?
No. The price is what the market pays today (106.00 TWD); the fair value is what the company's own numbers justify (148.01 TWD). For Bioteque the two are 42.01 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Bioteque worth?
The market values Bioteque at about 7.3B TWD (market capitalisation, as of Nov 6, 2026). Per share that is 106.00 TWD; our models calculate a fair value of 148.01 TWD per share.
What do the bullish and bearish scenarios say about 4107?
Our models span a range for Bioteque: cautious scenario 102.54 TWD, base 148.01 TWD, optimistic 195.50 TWD per share (as of Nov 6, 2026, price 106.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4107?
Bioteque trades at a price-to-earnings ratio of 12.5 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 148.01 TWD is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 17.7. Other multiples: P/B 2.0, P/S 3.3, EV/EBITDA 7.2.
How solid is the balance sheet of Bioteque (4107)?
Balance-sheet figures for Bioteque (as of Nov 6, 2026): return on equity 17.3%, debt of 0.04 per unit of equity. They feed the Quality Score of 79/100, which measures business quality independently of the share price.
How far is 4107 from its 52-week high?
Bioteque trades at 106.00 TWD, about 18% below its 52-week high of 129.00 TWD and 2% above the low of 104.00 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 148.01 TWD is for.
Which stocks are comparable to Bioteque?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bioteque stock attractive at the current price?
The data as of Nov 6, 2026: price 106.00 TWD, calculated fair value 148.01 TWD (+40%), Quality Score 79/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4107 calculated?
We run Bioteque through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 148.01 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bioteque currently trades 28% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bioteque (4107)?
The closing price on Nov 9, 2026 was 106.00 TWD. Our model-based fair value is 148.01 TWD, about +40% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bioteque right now?
The rarer combination: high quality (79/100) AND below fair value. That earns a closer look rather than a quick verdict. A fairly wide model range (102.54 TWD to 195.50 TWD) leaves room in how you read the outcome.
Where does the earnings growth of Bioteque (4107) come from?
Earnings per share at Bioteque grew +10.3 % a year from 2012 to 2023. Broken into its drivers: revenue per share +9.9 %, EBIT margin +2.8 %, tax rate −0.9 %, residual (interest, one-offs) −1.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Bioteque
How large is the market capitalisation of Bioteque (4107)?
The market capitalisation of Bioteque is 7.3B TWD (≈ $224M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bioteque (4107)?
The price-to-sales ratio of Bioteque is 3.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bioteque (4107)?
Earnings per share at Bioteque are 8.47 TWD (price ÷ EPS = P/E 12.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bioteque (4107)?
The dividend yield of Bioteque is 5.2% (payout 64.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bioteque (4107)?
The net margin of Bioteque is 26.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bioteque (4107)?
The return on equity (ROE) of Bioteque is 17.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bioteque (4107)?
On an EBIT basis the return on assets of Bioteque is 13.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bioteque (4107)?
The operating margin of Bioteque is 33.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bioteque (4107)?
Revenue at Bioteque is growing +10.9% versus a year earlier (3y avg +2.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bioteque (4107)?
Earnings per share at Bioteque are growing +82.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Bioteque (4107) hold?
Bioteque holds more cash than debt, 460M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Bioteque in the live analysis
One click puts Bioteque on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026